Insmed prices $100M offering for Arikayce work
By Jennifer Boggs
Thursday, August 14, 2014
Insmed Inc. priced a $100.1 million public offering Wednesday, more than doubling its cash balance, to support work on Arikayce, which, after yielding mixed data earlier this year, now seems poised to become the first once-daily, inhaled antibiotic for nontuberculous mycobacteria (NTM) and Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.